Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma

Basit Öğe Kaydı
dc.authoridKose, Mehmet Faruk/0000-0001-6136-5597
dc.authoridTulunay, Gokhan/0000-0003-0440-0725
dc.authorwosidKose, Mehmet Faruk/ABE-9977-2021
dc.contributor.authorKose, M. Faruk
dc.contributor.authorMeydanli, M. Mutlu
dc.contributor.authorTulunay, Gokhan
dc.date.accessioned2024-08-04T20:15:20Z
dc.date.available2024-08-04T20:15:20Z
dc.date.issued2006
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAlthough the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the time from first relapse of their disease to death will be longer than the period from diagnosis to that first relapse. There is current evidence from prospective randomized trials that carboplatin combined with either paclitaxel or gemcitabine confers a progression-free survival advantage over platinum monotherapy for patients with platinum-sensitive relapsed ovarian cancer. Since the efficacy of paclitaxel/platinum and gemcitabine/carboplatin regimens appears to be comparable based on similar progression-free survival (both combinations confer a 3-month advantage), toxicity profiles should be taken into account when deciding on the combination to be used. The gemcitabine/carboplatin combination should be preferred in patients with underlying peripheral neuropathy. Since alopecia associated with paclitaxel can diminish the overall quality of life, the gemcitabine plus carboplatin combination may be preferable for patients in whom alopecia is a major consideration. This review provides an update on the role of the gemcitabine/carboplatin combination in platinum-sensitive recurrent ovarian cancer.en_US
dc.identifier.doi10.1586/14737140.6.3.437
dc.identifier.endpage443en_US
dc.identifier.issn1473-7140
dc.identifier.issue3en_US
dc.identifier.pmid16503860en_US
dc.identifier.scopus2-s2.0-33644907176en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage437en_US
dc.identifier.urihttps://doi.org/10.1586/14737140.6.3.437
dc.identifier.urihttps://hdl.handle.net/11616/94309
dc.identifier.volume6en_US
dc.identifier.wosWOS:000240922700022en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFuture Drugs Ltden_US
dc.relation.ispartofExpert Review of Anticancer Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcarboplatinen_US
dc.subjectgemcitabineen_US
dc.subjectpaclitaxelen_US
dc.subjectplatinum-sensitive diseaseen_US
dc.subjectrecurrent ovarian canceren_US
dc.titleGemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinomaen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu